IL6 and diabetic kidney disease: In the open-label phase 1 pilot study, it was also suggested that D + Q treatment of patients with diabetic kidney disease (DKD) resulted in a decrease in the adipose tissue or skin epidermal (expressing p16INK4a and p21CIP1) senescent cells and elimination of senescence-associated secretory phenotype factors such as interleukin IL-1α or IL-6 [88].